Researchers at Sanford Burnham Prebys and collaborators released DeepTarget, a computational platform that predicts anti-cancer mechanisms of small molecules by integrating multi-omic and chemical data. Published in npj Precision Oncology, the tool challenges one‑drug/one‑target assumptions and surfaced candidate mechanisms across diverse cancer-relevant pathways. DeepTarget uses machine learning to map probable drug–target interactions and downstream pathway effects, enabling hypothesis generation for repurposing or target validation. Developers positioned the tool as an accelerant for preclinical discovery, helping prioritize experiments and de-risk early-stage programs.